Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cyclacel Pharmaceuticals, Inc. - Common Stock
(NQ:
CYCC
)
6.365
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 11, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cyclacel Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
August 03, 2023
From
Cyclacel
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
July 18, 2023
Via
Benzinga
Why Cano Health Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
↗
June 20, 2023
Gainers
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
June 20, 2023
It's time for another dive into the biggest pre-market stock movers as we check out all the latest news for Tuesday morning!
Via
InvestorPlace
Recap: Cyclacel Pharmaceuticals Q1 Earnings
↗
May 11, 2023
Via
Benzinga
Oppenheimer Maintains Outperform Rating for Cyclacel Pharmaceuticals: Here's What You Need To Know
↗
March 07, 2023
Via
Benzinga
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
June 20, 2023
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740.
Via
Benzinga
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
May 11, 2023
From
Cyclacel
Via
GlobeNewswire
A Preview Of Cyclacel Pharmaceuticals's Earnings
↗
March 03, 2023
Via
Benzinga
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
May 04, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit
May 03, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Participate in March Investor Conferences
March 07, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
March 06, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023
From
Cyclacel
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
February 16, 2023
Via
Benzinga
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
January 30, 2023
From
Cyclacel
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
January 17, 2023
Via
Benzinga
Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
January 05, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
December 15, 2022
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022
From
Cyclacel
Via
GlobeNewswire
Earnings Outlook For Cyclacel Pharmaceuticals
↗
November 08, 2022
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
November 03, 2022
From
Cyclacel
Via
GlobeNewswire
Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
October 26, 2022
Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients
From
Cyclacel
Via
GlobeNewswire
Cyclacel Hosting Research & Development Day
October 24, 2022
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
October 13, 2022
- Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma -
From
Cyclacel
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
August 17, 2022
We've got the news behind the biggest pre-market stock movers for Wednesday morning that traders need to know about this morning!
Via
InvestorPlace
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday
↗
August 19, 2022
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday.
Via
Benzinga
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
↗
August 18, 2022
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66.
Via
Benzinga
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
↗
August 12, 2022
Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.
Via
Benzinga
Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session
↗
August 11, 2022
Gainers Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing of $8.0 million public offering.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
